A comprehensive review on glioma
Corresponding Author(s) : Dr.S.Kameshwaran
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 9 No. 2 (2021): 2021 Volume - 9 Issue - 2
Gliomas are essential mind tumors that are thought to get from neuroglial stem or forebear cells. Based on their histological appearance, they have been generally delegated astrocytic, oligodendroglial or ependymal tumors and relegated WHO grades I–IV, which show various levels of danger. Gigantic advancement in genomic, transcriptomic and epigenetic profiling has brought about new ideas of arranging and treating gliomas. Diffusely invading gliomas in grown-ups are presently isolated into three overall tumor bunches with particular normal chronicles, reactions to therapy and results: isocitrate dehydrogenase (IDH)- freak, 1p/19q co-erased tumors with generally oligodendroglial morphology that are related with the best visualization; IDH-freak, 1p/19q non-co-erased tumors with for the most part astrocytic histology that are related with transitional result; and IDH wild-type, for the most part higher WHO grade (III or IV) tumors that are related with helpless guess. Gliomas in youngsters are atomically particular from those in grown-ups, the lion's share being WHO grade I pilocytic astrocytomas described by encompassed development, good anticipation and incessant BRAF quality combinations or transformations. Ependymal tumors can be atomically partitioned into particular epigenetic subgroups as indicated by area and visualization.
Download CitationEndnote/Zotero/Mendeley (RIS)
2. Lopes MBS, The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta neuropathologica. 2017 Oct;
3. von Deimling A, Louis DN, von Ammon K, et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg. 1992 Aug. 77(2):295-301.
4. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007 May. 170(5):1445-53.
5. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer. 2007 Jul 1. 110(1):13-24.
6. Malmstrom A, Gronberg BH, Marosi C, et al; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep. 13(9):916-26.
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10. 352(10):987-96.
8. Huang J, Samson P, Perkins SM, Ansstas G, Chheda MG, DeWees TA, et al. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol. 2016 Nov 14. 49(3):333-43.
9. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006 Mar. 148(3):269-75; discussion 275.
10. Nelson R. FDA Expands Indication for Optune Device in Glioblastoma. Medscape Medical News. Available at http://www.medscape.com/viewarticle/852196. October 6, 2015; Accessed: June 15, 2019.